Alison Langley

2.2k total citations · 1 hit paper
12 papers, 1.5k citations indexed

About

Alison Langley is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Alison Langley has authored 12 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 11 papers in Epidemiology and 9 papers in Neurology. Recurrent topics in Alison Langley's work include Neuroendocrine Tumor Research Advances (11 papers), Neuroblastoma Research and Treatments (9 papers) and Lung Cancer Research Studies (9 papers). Alison Langley is often cited by papers focused on Neuroendocrine Tumor Research Advances (11 papers), Neuroblastoma Research and Treatments (9 papers) and Lung Cancer Research Studies (9 papers). Alison Langley collaborates with scholars based in United Kingdom, Germany and France. Alison Langley's co-authors include Philippe Ruszniewski, Martyn Caplin, Guido Rindi, Lucy Wall, Eva Sedláčková, Guillaume Cadiot, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan and Jaume Capdevila and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and BMC Cancer.

In The Last Decade

Alison Langley

11 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

2014 1.3k citations Martyn Caplin, Marianne Pavel et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison Langley United Kingdom	5	1.4k	1.3k	1.1k	97	74	12	1.5k
Séverine Martinez France	4	1.4k 1.0×	1.3k 1.0×	1.1k 1.0×	95 1.0×	70 0.9×	6	1.5k
Staffan Welin Sweden	11	804 0.6×	731 0.5×	612 0.5×	90 0.9×	72 1.0×	15	911
Anna Malczewska Poland	19	749 0.5×	704 0.5×	410 0.4×	36 0.4×	89 1.2×	37	902
Nitya Raj United States	15	563 0.4×	610 0.5×	403 0.4×	63 0.6×	173 2.3×	63	843
Valentina Andreasi Italy	21	756 0.5×	935 0.7×	402 0.4×	14 0.1×	185 2.5×	70	1.1k
Marianne E. Pavel Germany	5	564 0.4×	470 0.4×	369 0.3×	44 0.5×	29 0.4×	11	748
Maribel Lopera Sierra United States	9	514 0.4×	452 0.3×	353 0.3×	65 0.7×	36 0.5×	24	640
Jan-Paul Esser Netherlands	5	606 0.4×	485 0.4×	422 0.4×	45 0.5×	35 0.5×	6	751
Sven‐Petter Haugvik Norway	13	364 0.3×	419 0.3×	213 0.2×	18 0.2×	100 1.4×	21	525
Beth Chasen United States	11	369 0.3×	343 0.3×	261 0.2×	42 0.4×	78 1.1×	19	557

Countries citing papers authored by Alison Langley

Since Specialization

Citations

This map shows the geographic impact of Alison Langley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Langley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Langley more than expected).

Fields of papers citing papers by Alison Langley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Langley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Langley. The network helps show where Alison Langley may publish in the future.

Co-authorship network of co-authors of Alison Langley

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Langley. A scholar is included among the top collaborators of Alison Langley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Langley. Alison Langley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Dromain, Clarisse, Marianne Pavel, Philippe Ruszniewski, et al.. (2019). Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer. 19(1). 49 indexed citations

Caplin, Martyn, Marianne Pavel, Jarosław B. Ćwikła, et al.. (2016). Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocrine Related Cancer. 23(3). 191–199. 170 indexed citations

Wolin, Edward M., Martyn Caplin, Marianne Pavel, et al.. (2015). Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).. Journal of Clinical Oncology. 33(15_suppl). e15180–e15180. 3 indexed citations

Phan, Alexandria T., Martyn Caplin, Marianne Pavel, et al.. (2015). Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).. Journal of Clinical Oncology. 33(15_suppl). e15181–e15181. 2 indexed citations

Phan, Alexandria T., Martyn Caplin, Marianne Pavel, et al.. (2015). Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.. Journal of Clinical Oncology. 33(3_suppl). 233–233. 6 indexed citations

Dasari, Arvind, Alexandria T. Phan, Martyn Caplin, et al.. (2015). Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.. Journal of Clinical Oncology. 33(15_suppl). e15177–e15177. 2 indexed citations

Phan, Alexandria T., Martyn Caplin, Marianne Pavel, et al.. (2015). Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.. Journal of Clinical Oncology. 33(3_suppl). 367–367. 4 indexed citations

Wolin, Edward M., Martyn Caplin, Marianne Pavel, et al.. (2015). Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.. Journal of Clinical Oncology. 33(15_suppl). e15182–e15182. 3 indexed citations

Dasari, Arvind, Alexandria T. Phan, Martyn Caplin, et al.. (2015). Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study.. Journal of Clinical Oncology. 33(15_suppl). 4104–4104. 3 indexed citations

10.

Caplin, Martyn, Marianne Pavel, Jarosław B. Ćwikła, et al.. (2014). Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. New England Journal of Medicine. 371(3). 224–233. 1286 indexed citations breakdown →

11.

Caplin, Martyn, Philippe Ruszniewski, Marianne Pavel, et al.. (2014). Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.. Journal of Clinical Oncology. 32(15_suppl). 4107–4107. 14 indexed citations

12.

Poyade, Matthieu, et al.. (2011). Using virtual reality for the training of the Metallographic Replica technique used to inspect power plants by TECNATOM SA. RADAR (Glasgow School of Art). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact